Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:07 2024-03-28 pm EDT 5-day change 1st Jan Change
201 GBX +1.93% Intraday chart for Oxford Biomedica plc +3.18% -8.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake AN
Oxford Biomedica Secures New Deal, Expands Existing Agreements for Clinical Programs MT
Oxford Biomedica plc Announces Board Changes CI
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract AN
Oxford Biomedica plc Provides Earnings Guidance for the Year Ended December 31, 2023 and for the Fiscal Year 2024 CI
Barclays cuts Bank of Ireland to 'equal weight' AN
EnSilica hires new chief financial officer from Oxford Biomedica AN
EnSilica Appoints Oxford Biomedica Executive as CFO MT
Oxford Biomedica Completes EUR15 Million ABL Europe Acquisition MT
Institut Merieux ups stake in Oxford BioMedica toward 10% AN
Oxford Biomedica plc completed the acquisition of additional 3.2% stake in ABL EUROPE S.A.S. from TSGH ?6.1 million CI
Transcript : Oxford Biomedica plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024
Oxford BioMedica posts optimistic outlook on uptick in contract value AN
Oxford Biomedica plc Provides Business Update CI
Goldman lifts Landsec and British Land AN
Oxford Biomedica to Buy ABL Europe from Institut Mérieux MT
Oxford BioMedica buys ABL Europe for consideration of EUR15 million AN
Oxford Biomedica plc entered into a sale and purchase agreement to acquire additional 3.2% stake in ABL EUROPE S.A.S. from TSGH. CI
Oxford Biomedica plc entered into a sale and purchase agreement to acquire ABL EUROPE S.A.S. from TSGH for ?15 million. CI
Record down as managed assets decline AN
Citigroup cuts Wizz Air to 'sell' AN
Transcript : Oxford Biomedica plc - Special Call
BoA likes Dowlais; JPMorgan cuts Phoenix Group AN
DFS Furniture gains share of weak market AN
The FTSE 100 Closes Up on Eased Oil Prices, Anticipation Over US Interest Rates Decision DJ
Chart Oxford Biomedica plc
More charts
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.972 GBP
Average target price
4.154 GBP
Spread / Average Target
+110.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Oxford Biomedica plc - London S.E.
  4. News Oxford Biomedica plc
  5. Oxford BioMedica, Lonza, Fujifilm Eye UK's Vaccine Manufacturing Innovation Center